Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jun 8;8(9):1892-1898.
doi: 10.1016/j.ekir.2023.06.001. eCollection 2023 Sep.

Membranous Nephropathy After Exposure to Immune Checkpoint Inhibitors

Rayane Benyahia  1 , Helene Lazareth  2   3 , Adrien Flahault  2   3 , Vesna Brglez  4   5   6 , Barbara Seitz-Polski  4   5   6   7 , Samy El Fil  8 , Julien Mazières  9   10 , David Ribes  1 , Antoine Huart  1 , Magali Colombat  10   11 , Alexandre Karras  2   3 , Julie Belliere  1   10
Affiliations
Case Reports

Membranous Nephropathy After Exposure to Immune Checkpoint Inhibitors

Rayane Benyahia et al. Kidney Int Rep. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kidney biopsy from Case Number 1, confirming the diagnosis of anti-PLA2R ICI-associated MN and unraveling a full-house immunofluorescent pattern. (a) Masson’s trichrome staining (40× magnification). (b) Jones staining (×40 magnification). (c) Immunofluorescence for IgG (×40 magnification), IgA (×40 magnification), IgM (×40 magnification), C3 (×40 magnification), C1q (×40 magnification), kappa (×40 magnification), and lambda (×40 magnification) showing subepithelial deposition of IgG, IgA, IgM, C3, C1q, kappa light chains, and lambda light chains.
Figure 2
Figure 2
Anti-PLA2R ICI-associated MN evolution under rituximab therapy in Case Number 1. (a) Antiphospholipase A2 receptor (PLA2R) antibody titer over time (RU/ml). (b) Analysis of PLA2R domain recognition indicated that the anti-PLA2R epitope recognition was restricted to the CysR domain (RU/ml). (c) Serum albumin (g/l) and urine protein-to-creatinine ratio (g/g) over time. (d) creatininemia (μmol/l) over time.
See this image and copyright information in PMC

References

    1. Cortazar F.B., Kibbelaar Z.A., Glezerman I.G., et al. Clinical features and outcomes of immune checkpoint inhibitor–associated AKI: a multicenter study. JASN. 2020;31:435–446. doi: 10.1681/ASN.2019070676. - DOI - PMC - PubMed
    1. Sprangers B., Leaf D.E., Porta C., Soler M.J., Perazella M.A. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nat Rev Nephrol. 2022;18:794–805. doi: 10.1038/s41581-022-00630-8. - DOI - PubMed
    1. Kitchlu A., Jhaveri K.D., Wadhwani S., et al. A systematic review of immune checkpoint inhibitor–associated glomerular disease. Kidney Int Rep. 2021;6:66–77. doi: 10.1016/j.ekir.2020.10.002. - DOI - PMC - PubMed
    1. Wakabayashi K., Yamamoto S., Hara S., et al. Nivolumab-induced membranous nephropathy in a patient with stage IV lung adenocarcinoma. CEN Case Rep. 2022;11:171–176. doi: 10.1007/s13730-021-00645-3. - DOI - PMC - PubMed
    1. Mamlouk O., Selamet U., Machado S., et al. Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019;7:2. doi: 10.1186/s40425-018-0478-8. - DOI - PMC - PubMed

Publication types

LinkOut - more resources